Patheon NV (PTHN) Receiving Somewhat Positive News Coverage, Analysis Finds
Press coverage about Patheon NV (NASDAQ:PTHN) has trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Patheon NV earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1836126415201 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Head to Head Survey: Pacira Pharmaceuticals (PCRX) versus Patheon NV (NASDAQ:PTHN) (americanbankingnews.com)
- Thermo Fisher Scientific Prices Offering of Common Stock (finance.yahoo.com)
- Thermo Fisher Extends Cash Tender Offer for All Outstanding Shares of Patheon to Coordinate Offer Timing with Two Remaining Regulatory Approvals (finance.yahoo.com)
- Thermo Fisher Scientific Announces $1.5 Billion Offering of Common Stock (finance.yahoo.com)
- Patheon NV (PTHN) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
Shares of Patheon NV (NASDAQ:PTHN) opened at 34.96 on Friday. Patheon NV has a 52 week low of $23.72 and a 52 week high of $35.01. The firm has a 50-day moving average price of $34.90 and a 200 day moving average price of $31.21. The stock has a market cap of $5.07 billion and a price-to-earnings ratio of 44.82.
Patheon NV (NASDAQ:PTHN) last released its quarterly earnings results on Thursday, June 8th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. The firm had revenue of $483.40 million for the quarter, compared to analysts’ expectations of $466.08 million. The business’s revenue was up 3.2% on a year-over-year basis. On average, analysts forecast that Patheon NV will post $1.14 EPS for the current fiscal year.
Several analysts have issued reports on PTHN shares. Zacks Investment Research raised Patheon NV from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Saturday, June 10th. Jefferies Group LLC lowered Patheon NV from a “buy” rating to a “hold” rating and upped their target price for the stock from $32.00 to $35.00 in a research note on Tuesday, May 16th. Leerink Swann lowered Patheon NV from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $31.00 to $35.00 in a research note on Friday, June 9th. William Blair lowered Patheon NV from an “outperform” rating to a “market perform” rating in a research note on Monday, May 15th. Finally, Raymond James Financial, Inc. reaffirmed a “market perform” rating and issued a $35.00 target price on shares of Patheon NV in a research note on Thursday, June 8th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Patheon NV currently has an average rating of “Hold” and an average price target of $32.88.
COPYRIGHT VIOLATION WARNING: “Patheon NV (PTHN) Receiving Somewhat Positive News Coverage, Analysis Finds” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/patheon-nv-pthn-receiving-somewhat-positive-news-coverage-analysis-finds/1476436.html.
About Patheon NV
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with Analyst Ratings Network's FREE daily email newsletter.